Cancer drug 49 times more potent than Cisplatin
Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.
Jul 7, 2015
0
104
Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.
Jul 7, 2015
0
104
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six ...
May 25, 2015
0
261
Researchers have discovered a metabolic signature critical for the functioning of "cancer stem cells" that initiate tumor formation. The team also showed how to interfere with this metabolic mechanism in ovarian cancer, inhibiting ...
Jan 3, 2017
0
294
New research conducted at the University of Alabama at Birmingham has shown that a particular type of diet could help women with ovarian cancer to lose weight and improve their quality of life and cancer-related measures.
Jun 16, 2016
0
726
Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug (pembrolizumab) may be effective in treating several types of late-stage cancers ...
May 26, 2022
0
20
The first cancer patients are to receive doses of an innovative new drug that targets a master regulatory pathway in cells, as part of a new clinical trial.
Jan 3, 2022
0
19
Inside each ovarian tumor, there are good cells and bad cells. A new paper explains their roles:
May 20, 2016
0
78
Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives in a meaningful way. However, a new research study shows ...
Jul 3, 2019
0
4
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.
Jun 19, 2018
0
275
The first fluorescence-guided surgery on an ovarian cancer patient was performed using a cancer cell "homing device" and imaging agent created by a Purdue University researcher.
Sep 18, 2011
0
0